Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Summary
Bill S00011 aims to amend New York's public health law by requiring the disclosure of information related to non-invasive prenatal screening for chromosomal abnormalities. The bill mandates that entities providing such screenings must supply written notices that clearly outline the purpose, limitations, and risks associated with these tests. This includes the necessity for confirmatory diagnostic testing following a positive result and the distinction between screening and diagnostic purposes. Additionally, the bill requires the development of comprehensive informational materials by the commissioner, which will be made available in multiple languages to ensure accessibility for all patients.
Impact
If enacted, this bill will enhance the transparency and understanding of non-invasive prenatal screenings for both healthcare providers and patients. It will require healthcare practitioners to provide clear, standardized information about these tests, potentially leading to better-informed decisions by expectant parents. The bill will also necessitate updates to existing public health resources to include the latest recommendations from relevant medical organizations, thus aligning state practices with current medical standards.
Sentiment
The sentiment surrounding Bill S00011 has been overwhelmingly positive, as evidenced by unanimous votes in both the Senate Health Committee and the Senate Floor for its passage. The discussions indicate a strong consensus among legislators regarding the importance of informed consent and patient education in prenatal care.
Contention
There appears to be minimal contention regarding the bill, with no recorded opposition during committee discussions or voting. The unanimous support suggests that legislators agree on the necessity of providing clear information to patients about non-invasive prenatal screenings, although potential concerns about the implementation and effectiveness of the required disclosures may arise in future discussions.
Same As
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).